Article Text

FRI0343 Safety and efficacy of varicella vaccine in patients with juvenile rheumatic diseases: A five years experience
  1. G.S. Pileggi1,1,
  2. C.B.S. de Souza,
  3. V.P.L. Ferriani
  1. Pediatric Immunology and Rheumatology, School of Medicine - Sao Paulo University, ribeiro preto, Brazil


Background There are case reports of severe disseminated varicella-zoster virus (VZV) infections in patients on methotrexate (MTX) or anti-TNF therapy. The severity of these infections can be significantly reduced in those vaccinated

Objectives The aims of this study were: to evaluate the safety and immunogenicity of a two dose protocol of varicella vaccine (VV) in susceptible patients with Juvenile Rheumatic Diseases (JRD) on MTX or anti-TNF therapy and to describe the vaccination efficacy over an observational 5-year follow-up period

Methods Fifty patients with JRD (1-18 years) and no history of varicella were vaccinated with VV, 32 of them received two doses. IgG anti-VZV antibody (VZV-IgG) titers were measured by ELISA before, 4-6 weeks after each dose of VV, one and five years thereafter. Patients were monitored prospectively during 8 weeks for adverse events related to the vaccine and over a 5-year observational period for exposure to or occurrence of varicella

Results All 50 patients were using MTX (mean dose 16 mg/m2/week, range 10 to 27); 23 were also receiving prednisone (range 5-20mg/day) and 5 were on anti-TNF therapy. Seroconversion rates were 50% after one dose of VV1 and 87% (28/32) for patients who received two doses (p<0,01). All 4/32 who did not reach protective titers after two VV doses were taking anti-TNF therapy (3/4 have systemic JIA). The vaccination neither induced overt varicella episodes or severe adverse events, nor underlying disease flare-ups after one or two doses. Twenty patients that received one dose of VV1 completed the five-year period of follow-up. Eleven of them were seronegative after one year: 2/11 developed varicella, six received a VV booster and all became seropositive. Only the 3/20 that refused the booster remained susceptible in the evaluation after 5 years. Among the 28 seroconverted patients that received two doses of VV, only 55% maintained protective VZV-IgG titers after one year, however none of them developed herpes zoster or chickenpox during the follow-up period of 1-3 years, including those with direct exposure to the wild virus in their environmental

Conclusions VV should be recommended for seronegative patients for whom immunosuppressive or biological therapy is planned and a protocol with 2 doses of VV should be considered to reach protective titers. If patients are on anti-TNF alpha therapy, additional boosters may be necessary.

  1. Pileggi GCS; Souza, CBS; Ferriani, VPL. Safety and Immunogenicity of Varicella Vaccine in Patients With Juvenile Rheumatic Diseases Receiving Methotrexate and Corticosteroids. Arthritis Care & Research, v. 62, p. 1034-1039, 2010.

Disclosure of Interest None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.